Purchase this article with an account.
Mouhab Aljajeh, Tarek A. Shazly, Mark A. Latina; Intraocular Pressure Control Using Bimatoprost 0.03% Every Other Night Compared To Every Night. Invest. Ophthalmol. Vis. Sci. 2011;52(14):234.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To compare intraocular pressure (IOP) reduction profiles of Bimatoprost 0.03% administered every other night (QOD-HS) compared to every night (QHS) in patients with primary open angle glaucoma (POAG) and pseudoexfoliation glaucoma (PXFG).
A retrospective, chart review of 68 eyes of 45 consecutive patients, who were switched from QHS to QOD-HS Bimatoprost, due to intolerable conjunctival hyperemia, between May 2005 and May 2008. IOP in the morning (AM) and afternoon (PM) of the next day after administration (day 1) and the day after (day 2) on QOD-HS regimen was compared to IOP in the AM and PM when they were on QHS regimen, 4-6 weeks after switching to QOD-HS. Mean IOPs and mean diurnal IOP fluctuation on each regimen were compared using Student t-test.
Mean IOPs on QHS Bimatoprost were 15.9 +/- 3.4 mm Hg in the AM and 15.5 +/- 2.7 mm Hg in the PM, while mean IOPs on QOD-HS were 14 +/- 2 mm Hg (AM) and 14.2 +/- 2.5 mmHg (PM) on day 1, and 14.7 +/- 2.6 mm Hg (AM) and 14.4 +/- 2.4 mmHg (PM) on day 2 after administration. Difference between IOP fluctuation on QHS and QOD-HS day 1 and day 2 respectively were not significant (p= 0.87 and 0.94).
Every other night dosing of Bimatoprost was effective in controlling IOP in this select group of patients with POAG and PXFG who had troublesome side effects on Bimatoprost 0.03% QHS regimen, and may be considered as an alternative to every day treatment.
This PDF is available to Subscribers Only